# EDGAR Filing Document

**Accession Number:** 0000718937
**File Stem:** 0001213900-25-100410
**Filing Date:** 2025-10
**Character Count:** 17483
**Document Hash:** 60e8955f24694864fe5fac4748c27c4d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-100410.hdr.sgml**: 20251020

**ACCESSION NUMBER**: 0001213900-25-100410

**CONFORMED SUBMISSION TYPE**: DFAN14A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251020

**DATE AS OF CHANGE**: 20251020

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** STAAR SURGICAL CO
- **CENTRAL INDEX KEY:** 0000718937
- **STANDARD INDUSTRIAL CLASSIFICATION:** OPHTHALMIC GOODS [3851]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 953797439
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1227

**FILING VALUES:**
- **FORM TYPE:** DFAN14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-11634
- **FILM NUMBER:** 251404491

**BUSINESS ADDRESS:**
- **STREET 1:** 1911 WALKER AVE
- **CITY:** MONROVIA
- **STATE:** CA
- **ZIP:** 91016
- **BUSINESS PHONE:** 6263037902

**MAIL ADDRESS:**
- **STREET 1:** 1911 WALKER AVE
- **CITY:** MONROVIA
- **STATE:** CA
- **ZIP:** 91016

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** STAAR SURGICAL COMPANY
- **DATE OF NAME CHANGE:** 19920703
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BROADWOOD PARTNERS, L.P.
- **CENTRAL INDEX KEY:** 0001278386

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DFAN14A

**BUSINESS ADDRESS:**
- **STREET 1:** BROADWOOD CAPITAL INC.
- **STREET 2:** 156 WEST 56TH STREET, 3RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019
- **BUSINESS PHONE:** 212-508-5735

**MAIL ADDRESS:**
- **STREET 1:** BROADWOOD CAPITAL INC.
- **STREET 2:** 156 WEST 56TH STREET, 3RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BROADWOOD PARTNERS LP
- **DATE OF NAME CHANGE:** 20040202

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934**

**(Amendment No.)**

Filed by the Registrant ☐

Filed by a Party other than the Registrant ☒

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material under §240.14a-12

**STAAR Surgical Company**

(Name of Registrant as Specified In Its Charter)

**Broadwood Partners, L.P.**

**Broadwood Capital, Inc.**

**Neal C. Bradsher**

**Richard T. LeBuhn**

**Natalie R. Capasso**

**Raymond A. Myers**

**Jason J. Martin**

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required

☐ Fee paid previously with preliminary materials

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

On October 20, 2025, Broadwood Partners, L.P., collectively with its affiliates, issued a press release, a copy of which is attached hereto as [Exhibit 1](#a_001) and incorporated herein by reference, and updated its website, www.LetSTAARShine.com, a copy of which is attached hereto as [Exhibit 2](#f_001) and incorporated herein by reference.

**CERTAIN INFORMATION CONCERNING THE PARTICIPANTS**

Broadwood Partners, L.P., Broadwood Capital, Inc., Neal C. Bradsher, Richard T. LeBuhn, Natalie R. Capasso, Raymond A. Myers and Jason J. Martin (collectively, the "Participants") are participants in the solicitation of proxies from the stockholders of STAAR Surgical Company (the "Company") in connection with the special meeting of stockholders scheduled for October 23, 2025 (including any adjournments, postponements, reschedulings or continuations thereof, the "Special Meeting"). The Participants have filed a definitive proxy statement on Schedule 14A (the "Definitive Proxy Statement") and accompanying **GREEN** Proxy Card to be used in connection with any such solicitation of proxies from the Company's stockholders for the Special Meeting. **STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTICIPANTS HAVE FILED OR WILL FILE WITH THE U.S. SECURTIES AND EXCHANGE COMMISSION (THE "SEC") BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE SPECIAL MEETING AND additional information relating to the Participants and their direct or indirect interests, by security holdings or otherwise**. The Definitive Proxy Statement and accompanying **GREEN** Proxy Card have been furnished to some or all of the Company's stockholders and will be, along with other relevant documents, available at no charge on the SEC's website at https://www.sec.gov/.

Information about the Participants and a description of their direct or indirect interests, by security holdings or otherwise, is contained on an amendment to Schedule 13D filed by the Participants with the SEC on September 26, 2025 and is available [here](http://www.sec.gov/Archives/edgar/data/718937/000121390025092516/xslSCHEDULE_13D_X01/primary_doc.xml).

**Exhibit 1**

**Broadwood Partners Highlights Growing Opposition to STAAR Surgical's Proposed Sale to Alcon**

***Leading Proxy Advisory Firms ISS, Glass Lewis, and Egan-Jones, as well as Long-Term Shareholders Echo Broadwood's Concerns over Deeply Deficient Sale Process, Timing, and Price***

***Shareholders Representing More than 34% of STAAR's Outstanding Common Shares Have Publicly Opposed the Transaction***

 

***Broadwood Urges All Shareholders to Vote "<u>AGAINST</u>" the Proposed Acquisition***

NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates ("Broadwood" or "we") today commented on the increasing public opposition to the proposed acquisition of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) by Alcon Inc. ("Alcon") (NYSE: ALC). Broadwood continues to urge its fellow shareholders to vote on the **<u>GREEN</u>** Proxy Card "**<u>AGAINST</u>**" the transaction at a virtual Special Meeting of Stockholders to be held on October 23, 2025, at 8:30 a.m. (Pacific Time).

Neal C. Bradsher, Broadwood Founder and President, stated:

"It is clear the sale process that led to this proposed transaction was deeply flawed and conflicted from the beginning. This proposed transaction comes at the wrong time, following the wrong process, and at the wrong price. All three major shareholder advisory firms agree, in a rare example of unanimity among these independent experts. So too do numerous shareholders. We continue to urge our fellow shareholders to vote '**<u>AGAINST</u>**' the proposed transaction on the **<u>GREEN</u>** Proxy Card."

To date, shareholders representing more than 34% of STAAR's outstanding common shares – including Yunqi Capital, Defender Capital, CalSTRS, former STAAR CEO David Bailey, and former STAAR executive Pascal Aeschlimann – have communicated publicly that they oppose and intend to vote against the proposed acquisition of STAAR by Alcon.

Below is some commentary by these independent third-party shareholders and proxy advisory firms.

**<u>The Wrong Time</u>**

● "With recent positive projections and outlook released by management, **we see no compelling reason to sell STAAR at this time**." (Defender Capital, October 7, 2025)<sup>1</sup>

Exhibit 1-1

● "STAAR's own words confirm the issue that caused Alcon to reduce its offer: management's poor execution, not any change in market opportunity or the underlying technology. Indeed, **STAAR's forecasts—revealed in the proxy—show sales doubling by 2030**." (Aeschlimann and Bailey, September 23, 2025)

● "… [T]he transaction was announced immediately prior to disclosure of Q2 financial results, which were better than expected. Not only does this **timing invite further suspicion**, but the company has changed the manner in which it presents certain challenges, and it has become **increasingly pessimistic despite developments since announcement that have been more positive than negative**." (ISS, October 15, 2025)

● "**Shareholders deserve better. We believe the Company is significantly underestimating the strength of its business** – particularly with respect to its performance and outlook in its largest market, China. … The China market is recovering, STAAR has the trusted products and established sales channels to capitalize on this large and growing opportunity, and **Alcon's bid for STAAR is clearly opportunistic**." (Yunqi Capital, October 6, 2025)

● "… **STAAR is financially stable and, by its own accounting, anticipates a material and relatively near-term return to growth across several fundamental metrics**. Our own review thus puts us in a difficult position to suggest unaffiliated investors have been afforded sufficiently compelling quantitative cause to cede exposure to that upside in exchange for a one-time cash-out." (Glass Lewis, October 7, 2025)

● "**We believe this offer is opportunistic, having been negotiated in the aftermath of excess inventory challenges in China that disproportionately impacted the Company's near-term financial performance rather than its long-term growth potential**. This became evident following the Company's Q2 earnings announcement after the August 5th merger disclosure, which indicated that the inventory challenges in China were beginning to ease. … **These contradictory statements within such a short time frame raise serious questions about the transparency and consistency of management**, as well as the timing and intent behind the merger negotiations." (Egan-Jones, October 10, 2025)

**<u>The Wrong Process</u>**

● "… [W]e believe **available disclosure introduces a litany of concerns around procedural depth and efficacy**, with the board skirting a true market check, giving short shrift to at least two inbound expressions of interest (**transparency around another approach in April 2025 remains meager, seemingly even within the STAAR boardroom**) and leaning on a 'window shop' process with little practical likelihood of producing a competing offer for the Company." (Glass Lewis, October 7, 2025)

● "A Board focused on maximizing long-term shareholder value might be expected … to seek improved terms from Alcon—or to invite competing proposals that reflect STAAR's strategic scarcity, potential synergies, and credible independent worth. **To settle for less clearly leaves substantial value unavailable to shareholders and represents a significant gift to Alcon if the deal is approved**." (Aeschlimann and Bailey, September 23, 2025)

Exhibit 1-2

● "… [T]here are **valid reasons for shareholders to question whether the wider board was fully informed of potential interest**. These considerations are particularly troubling, as the board chair had a preexisting business relationship with the acquirer that concluded less than a year before the deal was announced. **These facts alone could prompt a shareholder to consider rejecting the offer**." (ISS, October 15, 2025)

● "According to STAAR's SEC filings, the Company's named executive officers, stand to make an estimated $55 million in compensation from the proposed merger with Alcon. This includes approximately $24 million for CEO Stephen Farrell, a staggering amount for just a few months of leadership since his appointment earlier this year. **We believe these payouts reveal a significant conflict of interest, providing blinding financial incentives for Mr. Farrell to push for a sale, both to the Board and shareholders, at a price far below the Company's intrinsic value, while bypassing a more robust and transparent process**." (Yunqi Capital, October 6, 2025)

● "[We] believe the merger was executed hastily, limiting the Board's ability to conduct thorough due diligence. **In our view, this rushed approach compromised the evaluation of strategic alternatives and overlooked opportunities that may have been better aligned with the Company's long-term interests and shareholder value**. The board did not actively reach out to any parties besides Alcon during this process." (Egan-Jones, October 10, 2025)

**<u>The Wrong Price</u>**

● "… [O]n a forward-looking basis, **the deal appears to track below sector buyout trends and toward an evident near-term trough in STAAR's historical valuation**, neither of which suggests the current offer should be considered decisively attractive." (Glass Lewis, October 7, 2025)

● **"** STAAR's own projections, shared with Alcon during merger discussions, anticipate growth from $260M in 2025 to nearly $500M by 2030. **At this growth level, valuation multiples of 25x–40x would apply, implying values between $28 and $44 per share—before any strategic premium** … Alcon's own M&A record suggests that premiums of 50–70% could reasonably be applied, lifting the valuation range into the $50+ zone—possibly as high as $60 in a competitive process." (Aeschlimann and Bailey, September 23, 2025)

● "[W]e believe **the current offer price disregards the groundbreaking potential of STAAR's ICL technology, which boasts an unparalleled growth trajectory**. Furthermore, the current offer discounts the tireless efforts of industry professionals who have poured their expertise into elevating STAAR's ICL technology to its current stature and value-creating potential." (Yunqi Capital, October 6, 2025)

● "… [I]t is important to recognize that **the company is working through the issues that led to its share price collapse** … [T]he results of **these efforts have seemingly been more positive than negative** since announcement of the transaction. Thus, it would not be unreasonable for shareholders that believe in the company's turnaround prospects to **place more emphasis on the company's historical trading range as an anchor for value**." (ISS, October 15, 2025)

● "**[W]e believe the price of $28 per share significantly undervalues STAAR. Firstly, the $28 per share merger consideration is discounted from the two previous offers from Alcon**, the first of which was $58/share in April 2024 and the second was $55/share + $7 contingent value in October 2024. Secondly, a discounted cash flow analysis undertaken by Broadwood, using the revised management projections … and a WACC of 8.1% ... yields an equity value range of $22 to $49.66. **If the initial management projections (supplied to Alcon) are used, the result is an equity value reference range of $25.34 to $56.94**." (Egan-Jones, October 10, 2025)

Broadwood encourages its fellow shareholders to review the full statements of these investors, which are available as resources at www.LetSTAARShine.com, along with Broadwood's presentation, proxy materials, and press releases. Broadwood continues to urges its fellow shareholders to vote "**<u>AGAINST</u>**" the proposed transaction on the **<u>GREEN</u>** Proxy Card.

<sup>1</sup> Permission to use quote neither sought nor obtained. Emphasis added.

Exhibit 1-3

**About Broadwood**

Broadwood Partners, L.P. is managed by Broadwood Capital, Inc. Broadwood Capital is a private investment firm based in New York City. Neal C. Bradsher is the President of Broadwood Capital.

**Certain Information Concerning the Participants**

Broadwood Partners, L.P., Broadwood Capital, Inc., Neal C. Bradsher, Richard T. LeBuhn, Natalie R. Capasso, Raymond A. Myers and Jason J. Martin (collectively, the "Participants") are participants in the solicitation of proxies from the shareholders of STAAR in connection with the special meeting of shareholders scheduled for October 23, 2025 (including any adjournments, postponements, reschedulings or continuations thereof, the "Special Meeting"). The Participants have filed a definitive proxy statement on Schedule 14A (the "Definitive Proxy Statement") and accompanying **GREEN** Proxy Card to be used in connection with any such solicitation of proxies from the Company's shareholders for the Special Meeting. **SHAREHOLDERS OF STAAR ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTICIPANTS HAVE FILED OR WILL FILE WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION (THE "SEC") BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE SPECIAL MEETING AND ADDITIONAL INFORMATION RELATING TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE**. The Definitive Proxy Statement and accompanying **GREEN** Proxy Card have been furnished to some or all of STAAR's shareholders and will be, along with other relevant documents, available at no charge on the SEC's website at https://www.sec.gov/.

Information about the Participants and a description of their direct or indirect interests, by security holdings or otherwise, is contained on an amendment to Schedule 13D filed by the Participants with the SEC on September 26, 2025 and is available [here](http://www.sec.gov/Archives/edgar/data/718937/000121390025092516/xslSCHEDULE_13D_X01/primary_doc.xml).

**Contacts**

**Investor Contacts**

John Ferguson / Joseph Mills

Saratoga Proxy Consulting LLC

jferguson@saratogaproxy.com

jmills@saratogaproxy.com

(212) 257-1311

(888) 368-0379

**Media Contacts**

Scott Deveau / Jeremy Jacobs

August Strategic Communications

Broadwood@AugustCo.com

(323) 892-5562

Exhibit 1-4

**Exhibit 2**

![](image_001.jpg)